JPM Global Healthcare C (acc) USD |
Performance History | 31/03/2024 |
Growth of 1,000 (EUR) |
Fund | 14.1 | 20.4 | -2.7 | 0.0 | 10.3 | |
+/-Cat | 2.9 | 3.7 | 7.1 | 0.8 | 3.6 | |
+/-Idx | - | -5.6 | -2.8 | 0.2 | 0.8 | |
Category: Sector Equity Healthcare | ||||||
Benchmarks: Morningstar Gbl Health TME ... |
Key Stats | ||
NAV 25/04/2024 | USD 603.23 | |
Day Change | -0.88% | |
Morningstar Category™ | Sector Equity Healthcare | |
ISIN | LU0432979887 | |
Fund Size (Mil) 25/04/2024 | USD 4142.26 | |
Share Class Size (Mil) 25/04/2024 | USD 375.50 | |
Max Initial Charge | - | |
Ongoing Charge 06/12/2023 | 1.00% |
Investment Objective: JPM Global Healthcare C (acc) USD |
To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally. |
Returns | |||||||||||||
|
Management | ||
Manager Name Start Date | ||
Holly Fleiss 09/06/2022 | ||
Dominic Valder 05/10/2022 | ||
Click here to see others | ||
Inception Date 02/10/2009 |
Advertisement |
Benchmarks | |
Fund Benchmark | Morningstar Benchmark |
MSCI World/Health Care NR USD | Morningstar Gbl Health TME NR USD |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for JPM Global Healthcare C (acc) USD | 31/03/2024 |
|
|
Top 5 Holdings | Sector | % |
Eli Lilly and Co | Healthcare | 9.01 |
UnitedHealth Group Inc | Healthcare | 7.66 |
Novo Nordisk A/S Class B | Healthcare | 5.96 |
AbbVie Inc | Healthcare | 5.17 |
Regeneron Pharmaceuticals Inc | Healthcare | 4.54 |
Increase Decrease New since last portfolio | ||
JPM Global Healthcare C (acc) USD |